Eyenovia Inc (EYEN) Quote

huge run now. maybe merger happened?

rumor of merger news on…..

….

mon or tues, per stocktwits

EYEN...........................................https://stockcharts.com/h-sc/ui?s=eyen&p=W&b=5&g=0&id=p86431144783

June 2 > Form 424B5 - Prospectus [Rule 424(b)(5)]

Trading float 2.75M shares

Yearly revenues average $4,790. per employee.

blasting off! weeee!!!

yup, holding up great for a friday!

she looks fixin to run

stocktwits said there may be a…

..

merger of some kind. dont know, dont care, but i like the past chart and how its moving post split.

it appears someone bought about……

…


$17mil worth (about 4mil shares) at about $4.40 pre market.

grabbed some on the dip. hi all.

Green dragon 🐉 in my dreams

EYEN....................................https://stockcharts.com/h-sc/ui?s=EYEN&p=W&b=5&g=0&id=p86431144783

Banging out the gate! Up 17% many catalysts inbound

Looking fantastic again today,Inbound co. Value 44m,zero borrow not even flinching and 242% fee!! Golden atm,merger final will probably be delayed because it’s non- binding but I think a binding one will be enough for run up,this isn’t an in-house scam merger,I see it’s optionable now,looking at calls/puts,they plan on this becoming a huge company,pps is 70% above sma50 so loading has been going on awhile,lots of run room until sma200 makes this an attractive opportunity for investors,especially since the new fins!

EYEN..................................................https://stockcharts.com/h-sc/ui?s=EYEN&p=W&b=5&g=0&id=p86431144783

Going to be a nice run up to Friday

Lowest fill was 1.75

Zero borrow this morning,they not loaning shares to short,I am buying bought 1.85(bids in for more if it drops)

EYEN.................................................p/m

Company News Out 5.30 pm Yesterday, Aftert Market Run As Well As Today, GLTA

EYEN.....................................................................https://stockcharts.com/h-sc/ui?s=eyen&p=W&b=5&g=0&id=p86431144783




longtimenoc

EYEN under $2

EYEN, under $2

EYEN, new 52 week low

EYEN, new 52 week low

EYEN, new 52 week low

EYEN, new 52 week low

EYEN, new 52 week low

EYEN , new 52/week low

EYEN...All out with a loss here...🥳

georgie18

Member Level
Re: georgie18 post# 70

Thursday, January 16, 2025 12:26:58 PM

Post#
74
of 74
EYEN...07...🥳...Averaging down on this dip...from my .12 Alert...

georgie18

Member Level
Re: None

Thursday, January 09, 2025 10:29:58 AM

Post#
670925
of 671550
EYEN...12...🥳... https://schrts.co/jpheeDNV ...Open Gap in the .30 range...

EYEN...07...🥳...Averaging down on this dip...from my .12 Alert...

georgie18

Member Level
Re: None

Thursday, January 09, 2025 10:29:58 AM

Post#
670925
of 671550
EYEN...12...🥳... https://schrts.co/jpheeDNV ...Open Gap in the .30 range...

1/6  -- Eyenovia (EYEN) said Monday it is exploring strategic alternatives for its business and has hired Chardan as a financial adviser.

..............,,,,On December 30, 2024, the Company entered into an Amended and Restated Sales Agreement (the “A&R Sales Agreement”) with Chardan Capital Markets, LLC (“Chardan”), as agent, which has been acknowledged and agreed by Leerink Partners LLC (“Leerink Partners”), with respect to the Company’s existing at-the-market offering program with an aggregate offering price of up to $50,000,000 of shares of common stock, par value $0.0001 per share, of the Company (the “Common Stock”). The A&R Sales Agreement amends and restates that certain Sales Agreement, dated December 14, 2021, by and between the Company and Leerink Partners (the “Initial Sales Agreement”) to, among other things, replace Leerink Partners with Chardan as sales agent. The Company sold an aggregate of $16,413,443 of shares of Common Stock under the Initial Sales Agreement. The Company will file a prospectus supplement relating to the offer and sale of the Common Stock pursuant to the A&R Sales Agreement, which will form a part of the Company’s Registration Statement on Form S-3 (File No. 333-282458), which was filed with the Securities and Exchange Commission on October 1, 2024 and declared effective on October 8, 2024. Subject to the terms and conditions of the A&R Sales Agreement, Chardan may sell shares of Common Stock by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended (the “Securities Act”). Chardan will use commercially reasonable efforts to sell the Common Stock from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay Chardan a commission equal to 3.0% of the gross sales proceeds of any Common Stock sold through Chardan under the A&R Sales Agreement. The Company is not obligated to make any sales of Common Stock under the A&R Sales Agreement. The offering of Common Stock will terminate upon the earlier of (i) the sale of all Common Stock subject to the A&R Sales Agreement or (ii) termination of the A&R Sales Agreement in accordance with its terms. The A&R Sales Agreement contains customary representations, warrantees and agreements between the Company and Chardan, including customary indemnification rights, including for liabilities under the Securities Act. The representations, warranties and covenants contained in the A&R Sales Agreement were made only for purposes of such agreement and as of specific dates and were solely for the benefit of the parties to such agreement. The foregoing description of the A&R Sales Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the A&R Sales Agreement, a copy of which is filed as Exhibit 1.1 hereto and is incorporated herein by reference. The legal opinion of Covington & Burling LLP relating to the shares of Common Stock being offered is filed herewith as Exhibit 5.1. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the Common Stock nor shall there be any sale of the Common Stock in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Item 8.01. Other Events. Termination of Prior ATM Prospectus On December 29, 2024, prior to entry into the A&R Sales Agreement, the Company notified Leerink Partners that it was suspending and terminating the prospectus, dated October 8, 2024, relating to the sale of up to $25,000,000 of Common Stock, that could be issued and sold pursuant to the Initial Sales Agreement. Financial Update As of December 26, 2024, the Company had cash and cash equivalents of $2.2 million. Also as of December 26, 2024, the Company owed $10.1 million in principal and accrued interest under the Loan and Security Agreement, dated November 22, 2022, as amended, with Avenue Capital Management II, L.P., as administrative agent and collateral agent, Avenue Venture Opportunities Fund, L.P., as a lender and Avenue Venture Opportunities Fund II, L.P., as a lender. Item 9.01. Exhibits..... 

EYEN...12...🥳... https://schrts.co/jpheeDNV ...Open Gap in the .30 range...

EYEN..................................https://stockcharts.com/h-sc/ui?s=EYEN&p=W&b=5&g=0&id=p86431144783

eyen....................................https://stockcharts.com/h-sc/ui?s=eyen&p=W&b=5&g=0&id=p86431144783




onit...............

.30 + 150%

8k keep an eye here 

Scam: selling 24 Million new shares at $0.10 , just before probable "Bankruptcy"!

NEW YORK, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that it has entered into a securities purchase agreement with a healthcare focused institutional investor for the purchase and sale of 12,081,785 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 24,163,570 shares of common stock in a registered direct offering at a combined offering price of $0.1076 per share and accompanying warrants. T

EYEN..............................https://stockcharts.com/h-sc/ui?s=EYEN&p=W&b=5&g=0&id=p86431144783

And then again, maybe not. You still up 200% or did you sell during that balloon ride

still holding.. see you at trips

just going to hold i dont care anymore im tired of wishing on a star..im better off spending my days with the prayer beads than this nonsense

eyen 3200 at .59 lets gooo

Have to agree with you. I was surprised at the size of this offering. Rather not go through this again so will lighten up or liquidate completely on the next strong upward move.

It cost the company a 40% decline and dilution at $0.40 in exchange for 2.5 months of added runway. Not long ago they raised another $5m from 2 investors at $0.62 + warrants (also dilutive). They hope Oct data will allow accelerated approval of Micropine but even if good and accelerated still 12 months from approval. They will still burn and need to raise multiple times between now and 12 months from now. Perhaps they will be able to do it at a higher stock price if the Oct data is good but unclear. To buy today you need to be very confident that Oct data will be excellent.

EYEN new 52 low